SCHEMBL4472820

SCHEMBL4472820

CCN(CCOCC(=O)O)S(=O)(=O)c1c(C)cc(OC)cc1C

nearest known ligand 0.50

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 20/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL493626 0.85 BDKRB1 (0.47) BDKRB1
SCHEMBL700853 0.85 BDKRB1 (0.62) BDKRB1
SCHEMBL493475 0.85 TSHR (0.40) BDKRB1
SCHEMBL15347791 0.84 BDKRB1 (0.61) BDKRB1
SCHEMBL4477913 0.83 BDKRB1 (0.49) BDKRB1
SCHEMBL2200190 0.81 BDKRB1 (0.52) BDKRB1
SCHEMBL3995079 0.80 BDKRB1 (0.43) BDKRB1
SCHEMBL700704 0.80 BDKRB1 (0.46) BDKRB1
SCHEMBL4349660 0.80 BDKRB1 (0.43) BDKRB1
SCHEMBL4299477 0.79 PDE4A (0.46) BDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538111-B2 Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain LABORATOIRES FOURNIER S.A. (FR) 2009-05-26 US disclosed
US-20060178360-A1 Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain LABORATOIRES FOURNIER S.A. (FR) 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178360-A1 Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain LTB4R2, BDKRB2, TBXA2R BDKRB1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.